Senior J&J head appointed by Synageva
pharmafile | September 23, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | J&J, JJ, rob bazemore, synageva
US biopharma firm Synageva has appointed Robert Bazemore as its chief operating officer.
Reporting directly to the president and chief executive of Synageva – Sanj Patel – Bazemore will oversee the launch of the company’s lead programme and will have responsibility for the its commercial, market access and medical affairs operations.
Bazemore has over 22 years of biopharma experience, with the last 12 years being spent at Johnson & Johnson in various roles including vice president, Ethicon New Growth Platforms and president of its Janssen Biotech unit.
Bazemore began his career at J&J in 2002 and held numerous senior commercial positions, having led the worldwide immunology portfolio strategy and the launches of multiple new products and indications.
“Rob is a seasoned biopharmaceutical executive with substantial commercial leadership experience and his proven track record launching global products makes him a valuable addition to the team,” says Patel.
Related Content

J&J seek approval for first drug to treat high-risk smoldering myeloma
Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression
Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …






